作者对佩罗纳德和迈因茨的回复：“钠-葡萄糖协同转运蛋白2抑制剂及其除葡萄糖尿作用外的作用机制” - Suppr | 超能文献

相似文献

1

Author's Reply to Peronard and Mayntz: "SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect".作者对佩罗纳德和迈因茨的回复：“钠-葡萄糖协同转运蛋白2抑制剂及其除葡萄糖尿作用外的作用机制”

Am J Cardiovasc Drugs. 2025 Jan;25(1):131-133. doi: 10.1007/s40256-024-00707-8. Epub 2024 Dec 16.

2

Comment on "SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect".关于《SGLT2抑制剂及其在降糖作用之外的作用机制》的评论

Am J Cardiovasc Drugs. 2025 Jan;25(1):129-130. doi: 10.1007/s40256-024-00706-9. Epub 2024 Dec 16.

3

SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art.SGLT2 抑制剂及其超越降血糖作用的机制。最新进展。

Am J Cardiovasc Drugs. 2024 Nov;24(6):707-718. doi: 10.1007/s40256-024-00673-1. Epub 2024 Aug 24.

4

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.SGLT2 抑制剂对肾脏的保护作用：在急性和慢性肾脏病中的作用。

Curr Diab Rep. 2022 Jan;22(1):39-52. doi: 10.1007/s11892-021-01442-z. Epub 2022 Feb 3.

5

Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.有机阴离子转运蛋白 OAT3 增强 SGLT2 抑制剂恩格列净的降血糖作用。

Am J Physiol Renal Physiol. 2018 Aug 1;315(2):F386-F394. doi: 10.1152/ajprenal.00503.2017. Epub 2018 Feb 7.

6

[SGLT2 inhibitors for heart and kidney].用于心脏和肾脏的钠-葡萄糖协同转运蛋白2抑制剂

Dtsch Med Wochenschr. 2023 Nov;148(22):1456-1461. doi: 10.1055/a-1971-3381. Epub 2023 Nov 2.

7

Author's reply: Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis.作者回复：钠-葡萄糖协同转运蛋白2抑制剂与肾小管间质性肾炎之间的详细因果关系。

Intern Med. 2023 Mar 1;62(5):819. doi: 10.2169/internalmedicine.0341-22. Epub 2022 Jul 22.

8

SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.在肾单位数量减少的肾脏中抑制 SGLT2：溶质转运和代谢的建模与分析。

Am J Physiol Renal Physiol. 2018 May 1;314(5):F969-F984. doi: 10.1152/ajprenal.00551.2017. Epub 2018 Jan 17.

9

Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.托格列净或根皮苷通过延长伸展对映异构体抑制 SGLT2，从而诱导食蟹猴尿糖排泄。

Am J Physiol Renal Physiol. 2014 Jun 15;306(12):F1520-33. doi: 10.1152/ajprenal.00076.2014. Epub 2014 Apr 23.

10

Author's Reply: "Beyond inflammation: Expanding the horizon on vascular risk assessment in inflammatory".作者回复：“超越炎症：拓展炎症性血管风险评估的视野”

Dig Liver Dis. 2025 Jul;57(7):1522-1523. doi: 10.1016/j.dld.2025.04.017. Epub 2025 May 5.

引用本文的文献

1

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.2型糖尿病和心血管疾病十年进展：钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂的进展——综述

Front Endocrinol (Lausanne). 2025 Jul 7;16:1605746. doi: 10.3389/fendo.2025.1605746. eCollection 2025.

本文引用的文献

1

SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art.SGLT2 抑制剂及其超越降血糖作用的机制。最新进展。

Am J Cardiovasc Drugs. 2024 Nov;24(6):707-718. doi: 10.1007/s40256-024-00673-1. Epub 2024 Aug 24.

2

Narrative Reviews: Flexible, Rigorous, and Practical.叙述性综述：灵活、严谨且实用。

J Grad Med Educ. 2022 Aug;14(4):414-417. doi: 10.4300/JGME-D-22-00480.1.

3

Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.慢性肾脏病患者中钠-葡萄糖共转运蛋白 2 抑制剂的骨折风险。